Multiple Sclerosis and Related Disorders

Dr. Douglas Goodin, director of the Multiple Sclerosis Center at UCSF Medical Center, is a neurologist and an internationally renowned expert in the treatment and research of multiple sclerosis.. He earned a bachelor of sciences degree in genetics and biochemistry at the University of Washington in Seattle; a master of sciences degree in molecular biology at Purdue University in Indiana; and a medical degree from the University of California, Irvine. He completed a residency in neurology at UCSF where he joined the medical center staff in 1982. In addition to multiple sclerosis, Goodin's research interests include various forms of dementia. Goodin also is a professor of neurology at UCSF.

• Section 1 Pathogenesis1. Immune regulation of multiple sclerosis   2. Neuropathology of MS  3. The good and the bad of neuroinflammation in multiple sclerosis  4. Demyelination in multiple sclerosis  5. Axonal loss in multiple sclerosis: Causes and mechanisms   6. Insights from magnetic resonance imaging  7. Infections and multiple sclerosis  8. The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatmentSection 2 Epidemiology and genetics9. Multiple sclerosis genetics  10. Genetics of primary progressive multiple sclerosis  11. The epidemiology of multiple sclerosis: insights to disease pathogenesisSection 3 Diagnosis and disease course12. Multiple Sclerosis: Diagnosis, differential diagnosis and clinical presentation  13. MRI mimics of multiple sclerosis  14. Diagnosis of multiple sclerosis  15. Clinical course of multiple sclerosis  16. Early prognosis of multiple sclerosis  17. Clinical outcome measures in multiple sclerosis  18. MRI outcomes in the diagnosis and disease course of multiple sclerosis   19. Multiple sclerosis in childrenSection 4 Treatment20. Clinical trials in multiple sclerosis  21. Glucocorticoid treatment of multiple sclerosis  22. Disease modifying agents in multiple sclerosis  23. Immunosuppressive treatments in multiple sclerosis  24. Symptomatic treatment and management of multiple sclerosis  25. Future treatment approaches to multiple sclerosis  Section 5 Other demyelinating diseases26. Neuromyelitis optica (Devic's syndrome)  27. Acute disseminated encephalomyelitis and other inflammatory demyelinating variants  28. Acute inflammatory myelopathies  Section 6 Capita selecta29. Clinical neurophysiology of multiple sclerosis  30. Cerebrospinal fluid analysis